Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
16.28 USD | +0.68% | -0.12% | +9.26% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.26% | 8.03B | B- | ||
-3.76% | 3.13B | B- | ||
+4.62% | 3.11B | B- | ||
+9.80% | 1.39B | - | ||
-21.25% | 1.32B | C- | ||
-20.24% | 1.29B | B | ||
-2.83% | 1.27B | - | ||
-14.08% | 1.13B | - | ||
+4.89% | 950M | D+ | ||
-15.31% | 888M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Elanco Animal Health Incorporated - Nyse
- Ratings Elanco Animal Health Incorporated